Janus-like effects of type I interferon in autoimmune diseases
In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remi...
Gespeichert in:
| Veröffentlicht in: | Immunological reviews 2012-07, Vol.248 (1), p.23-35 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 35 |
|---|---|
| container_issue | 1 |
| container_start_page | 23 |
| container_title | Immunological reviews |
| container_volume | 248 |
| creator | Axtell, Robert C. Raman, Chander |
| description | In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are non‐responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro‐inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1. |
| doi_str_mv | 10.1111/j.1600-065X.2012.01131.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3383665</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1028036150</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6111-cf9e2bc330cb2c33fb1ef7f224d1c982e859a59fc6fb48573a0fc67214e403bc3</originalsourceid><addsrcrecordid>eNqNkM1v1DAQxS0EotvCv4By5JIwtuN8HKiEKtpuVYqEoHAbOd4xeJuPrZ3A7n9fhy0ruOHLPGne73n0GEs4ZDy-N-uMFwApFOpbJoCLDDiXPNs-YYvD4ilbAAeViqoujthxCGsAXkqRP2dHQpRC1Uos2OmV7qeQtu6OErKWzBiSwSbjbkPJMnH9SN6SH_ooEz2Ng-u6qadk5QLpQOEFe2Z1G-jl4zxhX87ffz67TK8_XizP3l2npoj3psbWJBojJZhGxGEbTra0QuQrbupKUKVqrWprCtvklSqlhqhLwXPKQUbwhJ3uczdT09HKUD963eLGu077HQ7a4b-b3v3A78NPlLKSRaFiwOvHAD_cTxRG7Fww1La6p2EKyEFUIAuuIFqrvdX4IQRP9vANB5zrxzXOLePcMs714-_6cRvRV3-feQD_9B0Nb_eGX66l3X8H4_LDp1lFPt3zLoy0PfDa32FRylLh15sLLG-u4BYuz_FWPgBg3aPh</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1028036150</pqid></control><display><type>article</type><title>Janus-like effects of type I interferon in autoimmune diseases</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Axtell, Robert C. ; Raman, Chander</creator><creatorcontrib>Axtell, Robert C. ; Raman, Chander</creatorcontrib><description>In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are non‐responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro‐inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.</description><identifier>ISSN: 0105-2896</identifier><identifier>EISSN: 1600-065X</identifier><identifier>DOI: 10.1111/j.1600-065X.2012.01131.x</identifier><identifier>PMID: 22725952</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Animals ; Autoimmune diseases ; Autoimmune Diseases - drug therapy ; Autoimmune Diseases - immunology ; Autoimmune Diseases - metabolism ; autoimmunity ; beta -Interferon ; Disease Models, Animal ; Encephalomyelitis - drug therapy ; Encephalomyelitis - immunology ; Encephalomyelitis - metabolism ; Helper cells ; Humans ; IL-7 ; Immunomodulation ; Inflammation ; Interferon ; Interferon Type I - adverse effects ; Interferon Type I - metabolism ; Interferon Type I - therapeutic use ; Interferon-beta - adverse effects ; Interferon-beta - metabolism ; Interferon-beta - therapeutic use ; Lymphocytes T ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Neuromyelitis ; Reviews ; Th1 ; Th1 Cells - immunology ; Th1 Cells - metabolism ; Th17 ; Th17 Cells - immunology ; Th17 Cells - metabolism</subject><ispartof>Immunological reviews, 2012-07, Vol.248 (1), p.23-35</ispartof><rights>2012 John Wiley & Sons A/S</rights><rights>2012 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6111-cf9e2bc330cb2c33fb1ef7f224d1c982e859a59fc6fb48573a0fc67214e403bc3</citedby><cites>FETCH-LOGICAL-c6111-cf9e2bc330cb2c33fb1ef7f224d1c982e859a59fc6fb48573a0fc67214e403bc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-065X.2012.01131.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-065X.2012.01131.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,776,780,881,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22725952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Axtell, Robert C.</creatorcontrib><creatorcontrib>Raman, Chander</creatorcontrib><title>Janus-like effects of type I interferon in autoimmune diseases</title><title>Immunological reviews</title><addtitle>Immunol Rev</addtitle><description>In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are non‐responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro‐inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.</description><subject>Animals</subject><subject>Autoimmune diseases</subject><subject>Autoimmune Diseases - drug therapy</subject><subject>Autoimmune Diseases - immunology</subject><subject>Autoimmune Diseases - metabolism</subject><subject>autoimmunity</subject><subject>beta -Interferon</subject><subject>Disease Models, Animal</subject><subject>Encephalomyelitis - drug therapy</subject><subject>Encephalomyelitis - immunology</subject><subject>Encephalomyelitis - metabolism</subject><subject>Helper cells</subject><subject>Humans</subject><subject>IL-7</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Interferon</subject><subject>Interferon Type I - adverse effects</subject><subject>Interferon Type I - metabolism</subject><subject>Interferon Type I - therapeutic use</subject><subject>Interferon-beta - adverse effects</subject><subject>Interferon-beta - metabolism</subject><subject>Interferon-beta - therapeutic use</subject><subject>Lymphocytes T</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Neuromyelitis</subject><subject>Reviews</subject><subject>Th1</subject><subject>Th1 Cells - immunology</subject><subject>Th1 Cells - metabolism</subject><subject>Th17</subject><subject>Th17 Cells - immunology</subject><subject>Th17 Cells - metabolism</subject><issn>0105-2896</issn><issn>1600-065X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1v1DAQxS0EotvCv4By5JIwtuN8HKiEKtpuVYqEoHAbOd4xeJuPrZ3A7n9fhy0ruOHLPGne73n0GEs4ZDy-N-uMFwApFOpbJoCLDDiXPNs-YYvD4ilbAAeViqoujthxCGsAXkqRP2dHQpRC1Uos2OmV7qeQtu6OErKWzBiSwSbjbkPJMnH9SN6SH_ooEz2Ng-u6qadk5QLpQOEFe2Z1G-jl4zxhX87ffz67TK8_XizP3l2npoj3psbWJBojJZhGxGEbTra0QuQrbupKUKVqrWprCtvklSqlhqhLwXPKQUbwhJ3uczdT09HKUD963eLGu077HQ7a4b-b3v3A78NPlLKSRaFiwOvHAD_cTxRG7Fww1La6p2EKyEFUIAuuIFqrvdX4IQRP9vANB5zrxzXOLePcMs714-_6cRvRV3-feQD_9B0Nb_eGX66l3X8H4_LDp1lFPt3zLoy0PfDa32FRylLh15sLLG-u4BYuz_FWPgBg3aPh</recordid><startdate>201207</startdate><enddate>201207</enddate><creator>Axtell, Robert C.</creator><creator>Raman, Chander</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>201207</creationdate><title>Janus-like effects of type I interferon in autoimmune diseases</title><author>Axtell, Robert C. ; Raman, Chander</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6111-cf9e2bc330cb2c33fb1ef7f224d1c982e859a59fc6fb48573a0fc67214e403bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Autoimmune diseases</topic><topic>Autoimmune Diseases - drug therapy</topic><topic>Autoimmune Diseases - immunology</topic><topic>Autoimmune Diseases - metabolism</topic><topic>autoimmunity</topic><topic>beta -Interferon</topic><topic>Disease Models, Animal</topic><topic>Encephalomyelitis - drug therapy</topic><topic>Encephalomyelitis - immunology</topic><topic>Encephalomyelitis - metabolism</topic><topic>Helper cells</topic><topic>Humans</topic><topic>IL-7</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Interferon</topic><topic>Interferon Type I - adverse effects</topic><topic>Interferon Type I - metabolism</topic><topic>Interferon Type I - therapeutic use</topic><topic>Interferon-beta - adverse effects</topic><topic>Interferon-beta - metabolism</topic><topic>Interferon-beta - therapeutic use</topic><topic>Lymphocytes T</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Neuromyelitis</topic><topic>Reviews</topic><topic>Th1</topic><topic>Th1 Cells - immunology</topic><topic>Th1 Cells - metabolism</topic><topic>Th17</topic><topic>Th17 Cells - immunology</topic><topic>Th17 Cells - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Axtell, Robert C.</creatorcontrib><creatorcontrib>Raman, Chander</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Immunological reviews</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Axtell, Robert C.</au><au>Raman, Chander</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Janus-like effects of type I interferon in autoimmune diseases</atitle><jtitle>Immunological reviews</jtitle><addtitle>Immunol Rev</addtitle><date>2012-07</date><risdate>2012</risdate><volume>248</volume><issue>1</issue><spage>23</spage><epage>35</epage><pages>23-35</pages><issn>0105-2896</issn><eissn>1600-065X</eissn><abstract>In multiple sclerosis, type I interferon (IFN) is considered immune‐modulatory, and recombinant forms of IFN‐β are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing‐remitting multiple sclerosis (RRMS) population, 30–50% of MS patients are non‐responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro‐inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22725952</pmid><doi>10.1111/j.1600-065X.2012.01131.x</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0105-2896 |
| ispartof | Immunological reviews, 2012-07, Vol.248 (1), p.23-35 |
| issn | 0105-2896 1600-065X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3383665 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Animals Autoimmune diseases Autoimmune Diseases - drug therapy Autoimmune Diseases - immunology Autoimmune Diseases - metabolism autoimmunity beta -Interferon Disease Models, Animal Encephalomyelitis - drug therapy Encephalomyelitis - immunology Encephalomyelitis - metabolism Helper cells Humans IL-7 Immunomodulation Inflammation Interferon Interferon Type I - adverse effects Interferon Type I - metabolism Interferon Type I - therapeutic use Interferon-beta - adverse effects Interferon-beta - metabolism Interferon-beta - therapeutic use Lymphocytes T Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Neuromyelitis Reviews Th1 Th1 Cells - immunology Th1 Cells - metabolism Th17 Th17 Cells - immunology Th17 Cells - metabolism |
| title | Janus-like effects of type I interferon in autoimmune diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T12%3A26%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Janus-like%20effects%20of%20type%20I%20interferon%20in%20autoimmune%20diseases&rft.jtitle=Immunological%20reviews&rft.au=Axtell,%20Robert%20C.&rft.date=2012-07&rft.volume=248&rft.issue=1&rft.spage=23&rft.epage=35&rft.pages=23-35&rft.issn=0105-2896&rft.eissn=1600-065X&rft_id=info:doi/10.1111/j.1600-065X.2012.01131.x&rft_dat=%3Cproquest_pubme%3E1028036150%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1028036150&rft_id=info:pmid/22725952&rfr_iscdi=true |